Literature DB >> 16085137

Sensitive HPLC method for quantitation of paclitaxel (Genexol in biological samples with application to preclinical pharmacokinetics and biodistribution.

Sung Chul Kim1, Jaewon Yu, Jang Won Lee, Eun-Seok Park, Sang-Cheol Chi.   

Abstract

A sensitive, specific and reproducible HPLC method has been developed and validated for the quantitative determination of paclitaxel in plasma, tissues and tumor of mice. Tissue specimens including liver, kidneys, spleen, lungs, heart and tumor were separately homogenized in bovine serum albumin (BSA, 40 g/l) in water. Plasma or tissue homogenates (0.1 ml) containing paclitaxel and internal standard (dimethyl-4,4'-dimethoxy-5,6,5',6'-dimethylene dioxy biphenyl-2',2' dicarboxylate (DDB), I.S.) were extracted by ethyl acetate (10 ml). A 4.6 mm x 250 mm ODS column was used to separate the components in biological samples with UV detection at 227 nm and gradient system was applied to a quantitation of paclitaxel consisting of acetonitrile-deionized water. The I.S. and paclitaxel were eluted at 13.7 and 18.0 min, respectively, and no interfering peaks were observed. Linear relationships (r(2) > 0.999) were obtained between the peak height ratios and the corresponding biological sample concentrations over the range of 0.1-20 microg/ml. The average intra- and inter-day variations (% R.S.D.s and % deviations) of the assay for biological samples were less than 10%. The LOD and LOQ were 5 and 10 ng/ml, respectively, for paclitaxel using a microsample volume (100 microl) of plasma sample. This HPLC method has been successfully applied for the determination of paclitaxel in pharmacokinetic and biodistribution study in after administration of 50 mg equivalent paclitaxel/kg dose of paclitaxel-loaded polymeric micelle and 20 mg equivalent paclitaxel/kg dose of Taxol to female SPF C57BL/6 mice.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16085137     DOI: 10.1016/j.jpba.2005.02.023

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  11 in total

1.  Substituents at the C3' and C3'N positions are critical for taxanes to overcome acquired resistance of cancer cells to paclitaxel.

Authors:  Michael Jelínek; Kamila Balušíková; Petr Daniel; Vlasta Němcová-Fürstová; Palani Kirubakaran; Martin Jaček; Longfei Wei; Xin Wang; Jiří Vondrášek; Iwao Ojima; Jan Kovář
Journal:  Toxicol Appl Pharmacol       Date:  2018-04-04       Impact factor: 4.219

2.  Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model?

Authors:  Wei Yang; Muneeb Ahmed; Mostafa Elian; El-Shymma A Hady; Tatyana S Levchenko; Rupa R Sawant; Sabina Signoretti; Michael Collins; Vladimir P Torchilin; S Nahum Goldberg
Journal:  Radiology       Date:  2010-09-21       Impact factor: 11.105

3.  Pharmacokinetic study of 3-in-1 poly(ethylene glycol)-block-poly(D, L-lactic acid) micelles carrying paclitaxel, 17-allylamino-17-demethoxygeldanamycin, and rapamycin.

Authors:  Ho-Chul Shin; Hyunah Cho; Tsz Chung Lai; Kevin R Kozak; Jill M Kolesar; Glen S Kwon
Journal:  J Control Release       Date:  2012-04-23       Impact factor: 9.776

4.  Pharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenografts.

Authors:  Xinghe Wang; Gang Zhao; Sang Van; Nan Jiang; Lei Yu; David Vera; Stephen B Howell
Journal:  Cancer Chemother Pharmacol       Date:  2009-07-11       Impact factor: 3.333

5.  Pretreatment of Shaoyao Gancao Decoction () alters pharmacokinetics of intravenous paclitaxel in rats.

Authors:  Yang Wang; Xi Huang; Mei-Zuo Zhong; Ruo-Huang Lu; Zi-An Xia; Rong Fan; Bo Liu; Wei Huang; Ping-Ping Gan
Journal:  Chin J Integr Med       Date:  2016-09-27       Impact factor: 1.978

6.  Micelles of different morphologies--advantages of worm-like filomicelles of PEO-PCL in paclitaxel delivery.

Authors:  Shenshen Cai; Kandaswamy Vijayan; Debbie Cheng; Eliana M Lima; Dennis E Discher
Journal:  Pharm Res       Date:  2007-06-13       Impact factor: 4.200

7.  Ultra-sensitive quantification of paclitaxel using selective solid-phase extraction in conjunction with reversed-phase capillary liquid chromatography/tandem mass spectrometry.

Authors:  Haoying Yu; Robert M Straubinger; Jin Cao; Hao Wang; Jun Qu
Journal:  J Chromatogr A       Date:  2008-09-19       Impact factor: 4.759

8.  Rapid and sensitive liquid chromatographic method for determination of Paclitaxel from parenteral formulation and nanoparticles.

Authors:  S Kollipara; G Bende; R N Saha
Journal:  Indian J Pharm Sci       Date:  2010-07       Impact factor: 0.975

9.  Preclinical efficacy studies of a novel nanoparticle-based formulation of paclitaxel that out-performs Abraxane.

Authors:  Zhongling Feng; Gang Zhao; Lei Yu; David Gough; Stephen B Howell
Journal:  Cancer Chemother Pharmacol       Date:  2009-08-15       Impact factor: 3.333

10.  The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells.

Authors:  Yuanyuan Xu; Ming Shen; Yiming Li; Ying Sun; Yanwei Teng; Yi Wang; Yourong Duan
Journal:  Oncotarget       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.